
iShares NASDAQ US Biotechnology UCITS ETF
iShares NASDAQ US Biotechnology UCITS ETF (GB:BTEC) Price & Chart
GB:BTEC ETF Chart & Stats
- Day’s Range
- $10.07 - $10.27
- 52-Week Range
- $8.00 - $10.98
- Previous Close
- $10.19
- Volume
- 149.67K
- Average Volume (3M)
- 277.66K
- AUM
- 1.30B
- NAV
- 10.06
- Expense Ratio
- 0.37%
- Holdings Count
- 246
- Beta
- 0.85
- Inception Date
- Oct 19, 2017
- Last Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
- Shares Outstanding
- 115,261,215
- Standard Deviation
- N/A
ETF Overview
iShares NASDAQ US Biotechnology UCITS ETF
The iShares NASDAQ US Biotechnology UCITS ETF, trading under the ticker IVBUF, is a specialized exchange-traded fund meticulously designed for investors seeking focused exposure to the burgeoning biotechnology sector within the broader health care industry. This ETF offers a compelling gateway into a niche market driven by innovation, where cutting-edge biomedical research and development are transforming the landscape of modern medicine. By investing in IVBUF, you tap into a curated portfolio that tracks the performance of leading biotechnology companies listed on the NASDAQ, a hub renowned for housing some of the most dynamic and forward-thinking enterprises in the world. This sector-focused fund is uniquely positioned to capitalize on the rapid advancements in genetic engineering, pharmaceuticals, and biotechnology, sectors characterized by their high growth potential and significant impact on public health outcomes. The iShares NASDAQ US Biotechnology UCITS ETF not only provides investors with diversification across multiple biotech stocks but also aligns with global trends emphasizing personalized medicine, bioinformatics, and the quest for breakthrough therapies. This makes it an ideal choice for investors who are not only looking to diversify their portfolios but also to invest in the future of healthcare innovation. Whether you're a seasoned investor or new to the field, IVBUF offers an exciting opportunity to be part of a transformative journey in the medical and technological frontier.
- Asset Class
- Equity
- Region
- North America
- Issuer
- iShares
- Index Tracked
- NASDAQ / Biotechnology
- Ticker Symbol
- GB:BTEC
GB:BTEC ETF News





Vertex Pharmaceuticals Inc. ($VRTX) announced an update on their ongoing clinical study. Study Overview: Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is studying patient experience with its official Phase 3b trial, titled


Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. Study Overview: Regeneron’s NCT07753148 study is formally titled “An Open-Label, Multi-Center Phase I Study to Investigate the Safety and
GB:BTEC ETF FAQ
What was GB:BTEC’s price range in the past 12 months?
What is the AUM of GB:BTEC?
Is GB:BTEC overvalued?
How many shares outstanding does GB:BTEC have?
GB:BTEC ETF Smart Score
Top 10 Holdings
| Name | Weight % |
|---|---|
| GILDGilead Sciences | 9.45% |
| AMGNAmgen Inc | 8.43% |
| VRTXVertex Pharmaceuticals Inc. | 8.04% |
| REGNRegeneron Pharmaceuticals | 6.40% |
| MRNAModerna | 5.26% |
| BIIBBiogen Inc. | 2.49% |
| RVMDRevolution Medicines, Inc. | 2.29% |
| ILMNIllumina | 2.12% |
| RPRXRoyalty Pharma PLC | 2.04% |
| ROIVRoivant Sciences Ltd. | 1.87% |
| Total | 48.38% |






